Patents by Inventor Robert Joseph Lechleider

Robert Joseph Lechleider has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination Therapy for the Treatment of Cancer
    Publication number: 20220041725
    Abstract: This invention relates to a pharmaceutical composition that comprises a first molecule that specifically binds HER2/neu and a second molecule that specifically binds a cell-surface receptor (or its ligand) that is involved in regulating an immune checkpoint (or the ligand thereof). The invention particularly relates to the embodiment wherein the second molecule binds to PD-1. The invention also relates to the use of such pharmaceutical compositions to treat cancer and other diseases.
    Type: Application
    Filed: June 18, 2021
    Publication date: February 10, 2022
    Applicant: MacroGenics, Inc.
    Inventors: Jon Marc Wigginton, Naimish Bharat Pandya, Robert Joseph Lechleider, Scott Koenig, Ezio Bonvini
  • Combination therapy for the treatment of cancer
    Patent number: 11078279
    Abstract: This invention relates to a pharmaceutical composition that comprises a first molecule that specifically binds HER2/neu and a second molecule that specifically binds a cell-surface receptor (or its ligand) that is involved in regulating an immune checkpoint (or the ligand thereof). The invention particularly relates to the embodiment wherein the second molecule binds to PD-1. The invention also relates to the use of such pharmaceutical compositions to treat cancer and other diseases.
    Type: Grant
    Filed: June 9, 2016
    Date of Patent: August 3, 2021
    Assignee: MacroGenics, Inc.
    Inventors: Jon Marc Wigginton, Naimish Bharat Pandya, Robert Joseph Lechleider, Scott Koenig, Ezio Bonvini
  • Dosing Regiments of Bi-Specific CD123 x CD3 Diabodies in the Treatment of Hematologic Malignancies
    Publication number: 20210061911
    Abstract: The present invention is directed to a dosing regimen for administering a CD123×CD3 bi-specific monovalent diabody to patients with a hematologic malignancy such as acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The invention particularly concerns the use of such a regimen for the sequence-optimized CD 123×CD3 bi-specific monovalent diabody “DART-A,” that is capable of simultaneous binding to CD 123 and CD3.
    Type: Application
    Filed: September 7, 2017
    Publication date: March 4, 2021
    Applicant: MacroGenics, Inc.
    Inventors: Jon Marc Wigginton, Ralph Froman Alderson, Robert Joseph Lechleider
  • Combination Therapy for the Treatment of Cancer
    Publication number: 20180298100
    Abstract: This invention relates to a pharmaceutical composition that comprises a first molecule that specifically binds HER2/neu and a second molecule that specifically binds a cell-surface receptor (or its ligand) that is involved in regulating an immune checkpoint (or the ligand thereof). The invention particularly relates to the embodiment wherein the second molecule binds to PD-1. The invention also relates to the use of such pharmaceutical compositions to treat cancer and other diseases.
    Type: Application
    Filed: June 9, 2016
    Publication date: October 18, 2018
    Applicant: MacroGenics, Inc.
    Inventors: Jon Marc Wigginton, Naimish Bharat Pandya, Robert Joseph Lechleider, Scott Koenig, Ezio Bonvini